Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 25th. </li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short interest changes in Wuxi Biologics, HK China Gas, Geely, Netease.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 25th. 
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short interest changes in Wuxi Biologics, HK China Gas, Geely, Netease.


HK Short Interest: Wuxi Biologics, HK China Gas, Geely, Netease

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Equity Capital Markets

Life Insurance  of India / Equity Capital Markets

<ul>
<li>Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.</li>
<li>This week we looked at the South Korean SK twins that are looking to list. In addition, LIC appears to be testing waters again.</li>
<li>Placement flows slowed down a bit with the mid-week HK holiday, although Australia and India blocks have continued to flow-in.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
This week we looked at the South Korean SK twins that are looking to list. In addition, LIC appears to be testing waters again.
Placement flows slowed down a bit with the mid-week HK holiday, although Australia and India blocks have continued to flow-in.


ECM Weekly (10th Apr 2022)- LIC, GoTo, Shieldus, One Store, China ADRs, Air NZ, Chrysos, Zhihu

Asset Allocation & Fund Positioning, Copley Fund Research

Steven Holden

Asset Allocation & Fund Positioning

Copley Fund Research

Copley Fund Research provide research and data on asset allocation among Global and Emerging Market equity funds.  The analysis details absolute and relative positioning across countries, sectors and industries together with highly granular data on single stock and single fund allocations.  The data is updated monthly with time series going back to January 2011.

Global Research - Analysis of 165 prominent Global equity funds, combined AUM $335bn
GEM Research - Analysis of 127 prominent global EM equity funds, combined AUM $250bn

Asset Allocation - Global and GEM Equity

Cross Asset Strategy

<ul>
<li>80% of active Asia Ex-Japan managers underperformed the benchmark in Q1</li>
<li>Value managers were the only Style group to outperform the benchmark, with Aggressive Growth and Growth some way behind</li>
<li>Underweights in NIO Inc, Meituan and overweights in HDFC Bank generated relative outperformance, but were outgunned by overweights in Sea Ltd, Mediatek Inc and underweights in the China state banks.</li>
</ul>


80% of active Asia Ex-Japan managers underperformed the benchmark in Q1
Value managers were the only Style group to outperform the benchmark, with Aggressive Growth and Growth some way behind
Underweights in NIO Inc, Meituan and overweights in HDFC Bank generated relative outperformance, but were outgunned by overweights in Sea Ltd, Mediatek Inc and underweights in the China state banks.


Asia Ex-Japan Active Funds.  Big Q1 Underperformance.

Alibaba Group Holding  / Equity Capital Markets

<ul>
<li>On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas regulators to China ADRs audits.</li>
<li>On 8th Mar 2022, Securities Exchange Commission (SEC) had added five China ADR names to its provisional list of issuers under HFCAA, which set the clock ticking for their delisting.</li>
<li>In this note, we'll talk about the latest developments and its implications.</li>
</ul>


On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas regulators to China ADRs audits.
On 8th Mar 2022, Securities Exchange Commission (SEC) had added five China ADR names to its provisional list of issuers under HFCAA, which set the clock ticking for their delisting.
In this note, we'll talk about the latest developments and its implications.


China ADRs Delisting - Tide Is Turning with CSRC Showing Signs of a Compromise

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 25. </li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short interest increases for Wuxi Biologics and Hong Kong &amp; China Gas. </li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 25. 
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short interest increases for Wuxi Biologics and Hong Kong &amp; China Gas. 


HK Short Interest: Wuxi Biologics, Kong Kong & China Gas

China

Meituan operates as a web based shopping platform for locally found consumer products and retail services. The Company offers deals of the day by selling vouchers on local services and entertainment, dining, delivery, and other services. Meituan provides its services throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Meituan (3690 HK)

HK Short Interest: Wuxi Biologics, HK China Gas, Geely, Netease

We highlight week on week short interest changes in Wuxi Biologics, HK China Gas, Geely, Netease based on latest HK SFC short aggregate report.

Ke Yan, CFA, FRM

ECM Weekly (10th Apr 2022)- LIC, GoTo, Shieldus, One Store, China ADRs, Air NZ, Chrysos, Zhihu

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Asia Ex-Japan Active Funds. Big Q1 Underperformance.

Active Asia Ex-Japan managers suffered one of their worst quarters in over a decade, with Value managers the only Style group to outperform the...

Steven Holden

China ADRs Delisting - Tide Is Turning with CSRC Showing Signs of a Compromise

On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas...

Sumeet Singh

HK Short Interest: Wuxi Biologics, Kong Kong & China Gas

We highlight weekly short interest increases for Wuxi Biologics (2269 HK) and Hong Kong & China Gas (3 HK), as well as short cover for Netease...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)